We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Black Diamond Therapeutics, Inc. is one of the twenty best biotech stocks.
TheFly reported on January 16 that Piper Sandler lowered the price target for BDTX to $8 from $9 and maintained an Overweight rating. The change coincided with the company’s revision of several models and price estimates throughout its biotechnology coverage, as well as an update to its 2026 Catalyst Tracker.
Separately, on December 3, 2025, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) released positive Phase 2 data for silevertinib in frontline NSCLC with non-classical EGFR mutations and demonstrated robust CNS activity with a 60% response rate. The company plans to negotiate with the FDA and carry out a randomized Phase 2 glioblastoma study in 2026 with funding through the second half of 2028.
Following this, on December 3, Guggenheim did not set a price objective for BDTX and instead reduced its recommendation from Buy to Neutral. The anticipated 2Q26 progression-free survival result and the planned Phase 3 trial’s increased risk were highlighted by analyst Brad Canino.
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is a clinical-stage oncology company that focuses on developing MasterKey therapies that target families of oncogenic mutations across tumors. Its pipeline includes brain-penetrant, precision small-molecule inhibitors in trials for EGFR and other mutation-driven cancers, which aim to address unmet needs in solid tumors.
While we acknowledge the potential of BDTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
Disclosure: None.
